Compare AXG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXG | FTRE |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | Hong Kong | United States |
| Employees | 33 | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.4M | 829.3M |
| IPO Year | N/A | 2023 |
| Metric | AXG | FTRE |
|---|---|---|
| Price | $3.55 | $13.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 115.3K | ★ 1.5M |
| Earning Date | 01-09-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $28.53 | N/A |
| Revenue Next Year | $54.60 | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $2.69 | $3.97 |
| 52 Week High | $4.75 | $18.67 |
| Indicator | AXG | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 55.18 |
| Support Level | $3.49 | $8.85 |
| Resistance Level | $3.94 | $18.26 |
| Average True Range (ATR) | 0.11 | 0.78 |
| MACD | -0.02 | -0.23 |
| Stochastic Oscillator | 10.34 | 9.69 |
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.